Clinical Trials · NCT00790699
Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
- Phase
- N/A
- Recruitment status
- Terminated
- Sponsor
- Texas Diabetes & Endocrinology, P.A.
- Enrollment
- 31
- Start date
- Aug 2009
- Locations
- 1 site, United States
- Primary endpoint
- The Primary Outcome Will be Measured by HbA1c Values Taken at Screening, Baseline and After Three Months.